Catalyst Pharmaceuticals, Inc.
Florida
United States
343 articles about Catalyst Pharmaceuticals, Inc.
-
Catalyst Pharmaceuticals to Hold Second Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, August 10th, 2021
7/26/2021
Catalyst Pharmaceuticals, Inc. today announced that it will release second quarter 2021 financial results after market close on Monday, August 9, 2021.
-
Catalyst Pharmaceuticals Announces Issuance of U.S. Patent 11,060,128 a Method of Use Patent with Claims Covering Firdapse®
7/19/2021
New patent bolsters intellectual property protection for Firdapse® First in a family of four pending patents for Firdapse® to issue
-
BioSpace Movers & Shakers, July 9
7/9/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
BioSpace Movers & Shakers, July 2
7/2/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of Directors
6/29/2021
Catalyst Pharmaceuticals, Inc. today announced the appointment of Molly Harper to the Company’s Board of Directors.
-
Catalyst Pharmaceuticals Announces Exclusive License and Supply Agreement with DyDo Pharma for the Development and Commercialization of Firdapse® in Japan
6/28/2021
Catalyst Pharmaceuticals, Inc. today announced that it has entered into an exclusive license and supply agreement with DyDo Pharma, Inc. (“DyDo Pharma”) for the development and commercialization of Firdapse.
-
Catalyst Pharmaceuticals, Inc.'s and KYE Pharmaceuticals' Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi
6/3/2021
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), and KYE Pharmaceuticals Inc. ("KYE"), today announced a positive decision in their lawsuit in Canadian Federal Court challenging Health Canada's approval of Medunik's New Drug Submission (NDS) for Ruzurgi®.
-
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
5/19/2021
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Catalyst’s Chief Executive Officer and Steven Miller, Ph.D. Chief Scientific Officer /COO, will participate in two upcoming investor conferences:
-
Catalyst Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update
5/10/2021
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today reported financial results for the first quarter ended March 31, 2021 and provided a business update.
-
Catalyst Pharmaceuticals to Hold First Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, May 11th, 2021
5/3/2021
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that it will release first quarter 2021 financial results after market close on Monday, May 10, 2021.
-
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
3/15/2021
- Firdapse ® Q4-20 Net Revenues of $31.0 Million, FY-20 Net Revenues of $119.1 Million - GAAP Net Income of $75.0 Million for Fiscal Year 2020 - $140.3 Million in Cash and Investments and No Funded Debt - Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow
-
Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 16th, 2021
3/4/2021
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it will release fourth quarter and year-end 2020 financial results after market close on Monday, March 15, 2021.
-
Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2021
2/22/2021
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced its support for Rare Disease Day 2021.
-
Catalyst Pharmaceuticals Announces Strategic Plan for Product Portfolio Expansion for Long-Term Success and Provides Corporate Update
1/6/2021
Company to Expand R&D Focus for Pipeline Growth to include Earlier Stage Programs and Validated Technology Platforms Firdapse® 2020 Net Revenues Estimate of approximately $118 Million; about 16% Increase From 2019 Ended 2020 with Estimated $140 Million in Cash and Investments Company Highlights Current Product Development Programs
-
Catalyst Pharmaceuticals to Hold Third Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, November 10th, 2020
11/2/2020
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it will release third quarter 2020 financial results after market close on Monday, November 9, 2020.
-
Catalyst Pharmaceuticals Announces Filing of Patent Infringement Actions Against Jacobus Pharmaceuticals and PantherRx
10/19/2020
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it has filed a lawsuit in the U.S. District Court for New Jersey against Jacobus Pharmaceuticals, Inc. (Jacobus), and a lawsuit in the U.S. District Court for the Western Di
-
Catalyst Pharmaceuticals has filed new patent infringement lawsuits against Jacobus Pharmaceuticals and PantherRX Rare LLC over a treatment for the rare autoimmune disease Lambert-Eaton Myasthenic Syndrome.
-
Catalyst Pharmaceuticals Announces Issuance of U.S. Patent for Firdapse®Issued Patent is the First Covering Firdapse®
10/6/2020
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a new U.S. patent to Catalyst Pharmaceuticals for Firdapse® (amifampridine), U.S. Patent No. 10,793,893, Met
-
Catalyst Pharmaceuticals is reeling this morning after a federal judge dismissed the company’s lawsuit against the U.S. Food and Drug Administration regarding the approval of a rival drug for a rare autoimmune disease from New Jersey-based Jacobus Pharmaceutical.
-
Catalyst Pharmaceuticals Announces Ruling on Lawsuit against the FDA and Intent to Appeal
9/29/2020
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that the federal judge handling Catalyst's case against the FDA has adopted the previously reported Report and Recommendation of the Magistrate Judge, granted summary judgment in favor of the FDA and Jacobus, and dismissed Catalyst's case.